Medicine and Dentistry
Molecular Diagnostics
100%
American Indian
100%
Pneumococcus Vaccine
100%
Serotype
100%
Disease
100%
Intention-to-Treat Analysis
100%
Staphylococcus Aureus
100%
Motavizumab
100%
Streptococcus Group A
100%
Soft Tissue Infection
100%
Pneumococcal Infection
100%
Conjugate Vaccine
66%
Vaccine
66%
Infection
42%
Meticillin
42%
Point of Care Systems
33%
Streptococcus Pneumoniae
33%
Bacterial Disease
33%
Disease Burden
33%
Toddlers
33%
Polysaccharide
33%
High Risk Population
33%
Clinical Management
16%
Antibiotics
16%
Wound
16%
Diabetes
14%
Amputation
14%
Keyphrases
Tribal Lands
100%
APACHE
100%
Native American
100%
Staphylococcus Aureus
100%
Children's Group
100%
Motavizumab
100%
White Mountains
100%
High Burden
100%
Methicillin-resistant S. Aureus
50%
Protein-polymer Conjugate
33%
Group Randomization
33%
Group-randomized Studies
33%
Efficacy Groups
33%
Cobas Liat
33%
Community-acquired
25%
Sterile Body Sites
25%
Obesity
25%
Diabetes
25%
Laboratory-based Surveillance
25%
Active Population
25%
Amputation
25%
Population-based Surveillance
25%
S. Aureus Infection
25%
Underlying Medical Conditions
25%
US Population
25%
Methicillin Resistance
25%
Age-specific Incidence
25%
Southwestern USA
9%
Autumn Season
9%
Pharmacology, Toxicology and Pharmaceutical Science
Pneumococcus Vaccine
100%
Soft Tissue Infection
100%
Streptococcus Group A
100%
Motavizumab
100%
Staphylococcus Aureus
100%
Disease
100%
Pneumococcal Infection
60%
Meticillin
42%
Infection
42%
Vaccine
40%
Conjugate Vaccine
40%
Polysaccharide
20%
Streptococcus Pneumoniae
20%
Wound
16%
Antibiotic Agent
16%